- Report
- March 2025
- 175 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- May 2024
- 140 Pages
Global
From €5936EUR$6,499USD£5,076GBP
- Drug Pipelines
- March 2025
- 280 Pages
Global
From €2740EUR$3,000USD£2,343GBP
- Report
- August 2024
- 150 Pages
Global
From €3534EUR$3,869USD£3,022GBP
- Report
- March 2023
- 115 Pages
Global
From €4110EUR$4,500USD£3,515GBP
- Report
- November 2023
- 30 Pages
Global
From €2512EUR$2,750USD£2,148GBP
- Drug Pipelines
- February 2022
- 154 Pages
Global
From €5206EUR$5,700USD£4,452GBP
- Report
- February 2022
- 308 Pages
Global
From €8677EUR$9,500USD£7,420GBP
Regorafenib is a drug used to treat metastatic colorectal cancer (mCRC). It is a multi-kinase inhibitor that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Regorafenib is used in combination with other chemotherapy drugs to treat mCRC that has progressed after treatment with other drugs. It is also used to treat gastrointestinal stromal tumors (GIST) that have progressed after treatment with other drugs.
Regorafenib is a relatively new drug and is not yet widely used in the treatment of mCRC. However, it has been shown to be effective in prolonging survival in patients with mCRC who have progressed after treatment with other drugs. It is also being studied in combination with other drugs for the treatment of other types of cancer.
Regorafenib is marketed by Bayer AG, Merck & Co., Inc., and Ono Pharmaceutical Co., Ltd. It is also available in generic form from several generic drug manufacturers. Show Less Read more
